MedTrace Logo

Kamuvudine-9 (K9) in Diabetic Macular Edema

NCT07458061 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-03-10

No results posted yet for this study

Summary

The objectives of this investigation are to assess:

1. whether oral K9 is safe in subjects with DME, and
2. whether oral K9 improves BCVA compared to oral placebo

Conditions

Interventions

DRUG

Placebo Tablet: BID

Placebo tablets BID

DRUG

Kamuvudine K9

Kamuvudine K9

Sponsors & Collaborators

  • Dr. Bryan Strelow

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2026-06-30
Completion
2026-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07458061 on ClinicalTrials.gov